Product Description
99% Purity CAS 28860-95-9 Carbidopa Powder Carbidopa
Product Description
Product Details
| Product name |
Carbidopa |
| Cas number |
28860-95-9 |
| Apperance |
White powder |
| MF |
C10H14N2O4 |
| MW |
226.23 |
Carbidopa is a peripheral decarboxylase inhibitor and is often used in combination with Levodopa for the treatment of Parkinson's disease. It increases the amount of levodopa entering the central nervous system by inhibiting the activity of peripheral dopa decarboxylase and reducing the conversion of levodopa into dopamine in peripheral tissues such as the intestine and blood, thereby enhancing its therapeutic effect and reducing peripheral side effects such as nausea, vomiting and hypotension. Capdopa itself has no therapeutic effect, but its combination preparations with levodopa (such as compound levodopa, trade name "Sinemet") can significantly improve the motor symptoms of patients with Parkinson's disease. This drug should be used under the guidance of a doctor. Common adverse reactions may include dizziness, abnormal involuntary movements or mental symptoms, etc.
Application&Function
Pharmacological effects and mechanisms of action
Capibdopa is a peripheral dopa decarboxylase inhibitor. It is not easy to pass through the blood-brain barrier by itself and does not participate in the metabolism of levodopa in the brain. However, it can selectively block the decarboxylation of peripheral levodopa into dopamine, minimizing the formation of peripheral dopamine to the greatest extent. Thus, a low dose of levodopa can pass through the blood-brain barrier more, allowing it to decarboxylate in the brain to form the effective blood concentration of dopamine. At the same time, it also reduces peripheral side effects.
Drug interactions
1. This product should not be used in combination with amantadine, prodicycline, benzopycline, or benzhexyl.
2. When used in combination with levodopa, vitamin B6 can be taken as an additional dose if necessary.
Precautions
1. Patients with glaucoma, mental illness, suspected history of skin cancer or melanoma are prohibited from using capiba. Pregnant and lactating women should avoid using it. 2. Use with caution in patients with severe cardiovascular or pulmonary diseases, bronchial asthma, liver and kidney diseases, endocrine system diseases, and those with a history of gastric ulcers or convulsions. Sudden drug withdrawal can cause malignant mental depression syndrome.
Specification
){kind=link}